Tolaney SM, Chan A, Petrakova K, Delaloge S, et al. AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer. J Clin Oncol 2023 Jun 22:JCO2202746. doi: 10.1200/JCO.22.02746.
PMID: 37348019